Tirofiban-Tchaikapharma belongs to group of medicines called antithrombotic agents. Tirofiban prevents platelets from sticking together and thus forming blood clots, which can reduce blood flow to the heart and cause chest pain and heart attacks.


Tirofiban-Tchaikapharma is indicated for the prevention of adult patients with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes. Patients who are most likely to benefit from Tirofiban-Tchaikapharma treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those who are likely to undergo an early percutaneous coronary intervention (PCI). Tirofiban-Tchaikapharma is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI.

Tirofiban-Tchaikapharma is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.

Subject to medical prescription.

Concentration and pharmaceutical form: 0.25 mg/ml concentrate for solution for infusion